Consensus CSL Limited OTC Markets

Stocks

CSLLY

US12637N2045

Pharmaceuticals

Market Closed - OTC Markets 16:00:00 2026-09-08 EDT			5-day change	1st Jan Change
31.55 ^USD	-0.19%		+3.00%	+9.55%

03:05am	Australian shares post six-week closing low as banks drag	RE
11:17pm	ASX Midday Sector Update: Energy Stocks Advance, Healthcare Sector Struggles	MT

ac0ce0ea6460904c1.MKDRniRszFctVq0fXeBlTgR1d9UxwhzOFGwDfxth5Sg.Rfa6p3Ia-BZgOt4tGpBWB1YcP7F9kXStTR5nIEsbyFJi4rDGHQiTAk8glQ~65058a782941742fba09ce1d8a83d59d

Analysts' recommendations: CSL Limited

08-17	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
06-25	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
05-11	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
03-20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-10	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
12-08	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11-10	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
11-06	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
11-06	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
25-10-29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
25-10-28	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
25-10-28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
25-10-28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
25-10-02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
25-07-31	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
25-07-11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
25-07-10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
24-10-24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
24-09-08	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
24-09-04	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
24-08-14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
24-03-05	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
24-02-13	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
24-02-12	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+3.72%
	CSL LIMITED					-2.42%
	MODERNA, INC.					-16.98%
	SAMSUNG BIOLOGICS CO.,LTD.					+36.63%
	UCB					+37.75%
	BIOGEN INC.					+11.47%
	INCYTE CORPORATION					+2.68%
	INNOVENT BIOLOGICS, INC.					+28.27%
	SWEDISH ORPHAN BIOVITRUM AB					+9.61%
	Average					+12.30%
	Weighted average by Cap.					+10.22%